Chloroquine attenuates thymic stromal lymphopoietin production via suppressing caspase-1 signaling in mast cells - 03/09/21
, Hi-Joon Park e, ⁎ 
| pagine | 10 |
| Iconografia | 8 |
| Video | 0 |
| Altro | 0 |
Abstract |
Thymic stromal lymphopoietin (TSLP) produced by mast cells is involved in allergic inflammation pathogenesis. Chloroquine (CQ) is known to be an anti-malarial drug; however, additional protective functions of CQ have been discovered. This study aims to clarify an anti-inflammatory effect of CQ through modulating TSLP levels using an in vitro model of phorbol myristate acetate (PMA) + A23187-activated human mast cell line (HMC-1) and an in vivo model of PMA-irritated ear edema. CQ treatment reduced the production and mRNA expression levels of TSLP in activated HMC-1 cells. CQ down-regulated caspase-1 (CASP1), MAPKs, and NF-κB levels enhanced by stimulation with PMA + A23187. Moreover, ear thickness in ear edema was suppressed following CQ treatment. CQ decreased CASP1 and NF-κB levels in the ear tissue. TSLP levels in the ear tissue and serum were reduced following CQ treatment. Collectively, the above findings elucidate that CQ inhibits the pro-inflammatory mechanisms of TSLP via the down-regulation of distinct intracellular signaling cascade in mast cells. Therefore, CQ may have protective roles against TSLP-mediated inflammatory disorders.
Il testo completo di questo articolo è disponibile in PDF.Graphical Abstract |
Highlights |
• | Chloroquine inhibits TSLP levels in activated mast cells. |
• | Chloroquine down-regulates caspase-1, MAPKs, and NF-κB levels in activated mast cells. |
• | Chloroquine reduces TSLP levels via down-regulating caspase-1 in ear edema. |
• | Chloroquine suppresses ear thickness in ear edema. |
Keywords : Chloroquine, Mast cells, Thymic stromal lymphopoietin, Caspase-1, Ear edema
Mappa
Vol 141
Articolo 111835- settembre 2021 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?
